Press Releases

May 16, 2018
– First dose-ranging study comparing pharmaceutical formulation of cannabidiol to placebo as add-on therapy in Lennox-Gastaut syndrome, a rare, severe and difficult to treat form of childhood-onset epilepsy – – Both doses significantly reduced drop seizure frequency in patients with poor seizure
May 08, 2018
- Positive unanimous vote at Epidiolex ® (cannabidiol) FDA Advisory Committee meeting - - NDA PDUFA goal date scheduled for June 27, 2018 - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company
May 08, 2018
LONDON and CARLSBAD, Calif. , May 08, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that
May 03, 2018
LONDON , May 03, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 8 May, 2018 its second
Apr 19, 2018
LONDON and CARLSBAD, Calif. , April 19, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW”, “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along
Apr 12, 2018
Long-Term Safety and Efficacy Data in Patients with Lennox-Gastaut Syndrome and Dravet Syndrome to be Presented LONDON , April 12, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and
Mar 13, 2018
LONDON and CARLSBAD, Calif. , March 13, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along
Mar 05, 2018
LONDON and CARLSBAD, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced
Feb 27, 2018
LONDON and CARLSBAD, Calif. , Feb. 27, 2018 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today
Feb 21, 2018
-Study did not meet its primary endpoint- -Company remains committed to continued development of GWP42006 for autism spectrum disorders and will continue to explore the product’s potential within the field of epilepsy- LONDON and CARLSBAD, Calif. , Feb.